// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

The measurement of a next-generation FVIII Mimetic, Mim8, using tissue factor triggered calibrated automated thrombography

A. Bowyer - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

FVIII

The novel bispecific antibody HMB-001 enhances the haemostatic response in models of Glanzmann Thrombasthenia by targeting FVIIa to activated platelets

M. Zivkovic - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Glanzmann thrombasthenia

Evithrom

The potential of pre-activated platelets to contribute to thrombus formation

I. De Simone - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Fibrinogen (IV)

The rare VWF non-canonical splice-site variant, c.8155+6T>A, causes type 3 von Willebrand disease in homozygosity and results in perinuclear retention of VWF in endothelial cells

M. Sims - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The role of Adenylyl Cyclase 6 in platelet cyclic-AMP signalling

B. Webb - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Prostacyclin

The role of anticoagulation in the management of tumour thrombosis: A single centre retrospective study

U. Faruqi - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

The SAXOPHONE Study; A Multi-Center, Multi-National Randomized Trial of Apixaban versus Standard of Care Anticoagulation for Thromboprophylaxis in Children with Congenital or Acquired Heart Disease

R. Payne - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

apixaban

The TFPIα C-terminal tail is essential for the synergistic enhancement of TFPIα mediated inhibition of FXa by protein S and FV-short.

M. Gierula - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

folitixorin calcium

The type and frequency of bleeds in 870 children with severe hemophilia A and B on primary prophylaxis: Data from the PedNet study group

H. van den Berg - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

FVIII

The uptake and utilisation of fatty acids by platelets.

M. Hindle - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The use of Obinutuzumab and Ofatumumab in the treatment of immune Thrombotic Thrombocytopenic Purpura

A. Doyle - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Thrombotic thrombocytopenic purpura

Obinutuzumab

The use of plasminogen activator inhibitor-1 specific Affimers as a tool to modulate fibrin clot properties and thrombosis risk

R. Altalhi - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

The validation of linear One-Stage Clotting Assays (OSCA) using fully automated Multi-Dilution Analysis (MDA) in the quantification of factor activity

K. Ram - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The validation of mixing test-specific cut-off in lupus anticoagulant mixing test interpretation for multiple reagents

O. Kumano - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Warfarin

The VarioPath project: Determining effect sizes of pathogenic variants in platelet disorder genes, using clinical data from 0.5M whole exome sequenced UK Biobank participants

J. Collins - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The WASH-complex subunit Strumpellin regulates integrin αIIbβ3 trafficking in murine platelets

M. Spindler - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Thrombocytopenia and Thrombosis associated with AstraZeneca ChAdOx1 nCoV-19 Vaccination – results of Australian centralized clinical triage system and functional assay testing system

V. CHEN - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Thrombocytopenia

N/A

Thrombolytic therapy in pulmonary embolism patients with thrombocytopenia: a systematic review

F. Ata - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary embolism

N/A

Thrombopoietin receptor agonists (TPO-RAs) in older patients with primary immune thrombocytopenia (ITP): effective and safe? Real World Data from the UK adult ITP registry.

P. Raheja - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Immune thrombocytopenia

N/A

Thromboprophylaxis during lower limb immobilisation after injury – a review of 2 years’ practice at King’s College Hospital, London.

E. Marrinan - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Heparin

Copyright © 2026. QuantiNova All rights reserved